ACIU Stock Analysis: Buy, Sell, or Hold?
ACIU - AC Immune SA
$2.47
0.02 (0.82%)
▲
5d:
+4.22%
30d:
-12.72%
90d:
-13.64%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When ACIU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ACIU shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ACIU shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: ACIU is currently trading at $2.47, which is considered fair relative to its 30-day fair value range of $2.27 to $2.76. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.1) compared to its historical average (16.5). At these levels, the market is pricing in 8.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ACIU is in a downtrend. Immediate support is located at $2.10, while resistance sits at $2.58.
Market Sentiment: ACIU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.68 (+254.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACIU is in a downtrend. Immediate support is located at $2.10, while resistance sits at $2.58.
Market Sentiment: ACIU has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.68 (+254.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.27 -
$2.76
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 254.4% below Wall St target ($8.68)
- NEUTRAL: Trading at premium valuation - market expects 8.5% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$2.27 -
$2.76
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.10
Resistance Level
$2.58
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.12
Wall Street Target
$8.68
(+254.4%)
Revenue Growth (YoY)
13.0%
Valuation Premium vs History
+8.5% premium
PE vs Historical
21.1 vs 16.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.5%
(market-implied from PE analysis)
1-Year Target
$2.66
(+9%)
2-Year Target
$2.88
(+18%)
3-Year Target
$3.13
(+28%)
3-Yr Target (if PE normalizes)
(PE: 21→17)
PE COMPRESSION
$2.44
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 24, 2026 11:06 AM ET
Data refreshes hourly during market hours. Next update: 12:06 PM
Data refreshes hourly during market hours. Next update: 12:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACIU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
